BIOTEC-NSTDA successfully developed an ELISA-based SARS-CoV-2 antibody test called COVYD-19. The development was a collaboration between two research teams at BIOTEC-NSTDA, i.e., Virology and Cell Technology and Monoclonal Antibody Production and Application.
Dr. Peera Jaruampornpan, Leader of BIOTEC Virology and Cell Technology Research Team, revealed that the developed assay is focused on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The test has been evaluated in collaboration with Armed Forces Research Institute of Medical Sciences (AFRIMS) using serum samples and validated with the WHO reference material. Results showed comparable sensitivity and specificity to imported tests.
This test is intended for laboratory use, not for home use, as scientific instrument is required to read the results. It is designed to support research on COVID-19 infection and vaccine development that require the measurement of SARS-CoV-2 antibody level in a large number of samples. Currently, the test is being used in a population study conducted by the Faculty of Medicine, Thammasat University to measure SARS-CoV-2 antibody level in 1,000 samples obtained from medical staff. Information on immunity among the population is crucial for the development of proper vaccine and public health management plan.
